Publications by authors named "Stine M Jensen"
Background/aim: The study aim was to analyze the feasibility and efficacy of palliative radiotherapy in patients receiving advanced/interventional pain therapy, such as epidural or spinal anesthesia or subcutaneous pump delivery of opioids. Endpoints such as pain relief, treatment in the last month of life and survival were evaluated.
Patients And Methods: Different baseline parameters including but not limited to age and Eastern Cooperative Oncology Group performance status (ECOG PS) were assessed.
Article Synopsis
- Muscle-specific kinase (MuSK) is crucial for creating and maintaining neuromuscular synapses, and its activation can help treat diseases affecting these connections, such as congenital myasthenia (CM).
- ARGX-119 is a novel humanized monoclonal antibody designed to specifically activate MuSK, improving neuromuscular junction function without disrupting the natural ligand, neural Agrin.
- In studies, ARGX-119 successfully improved neuromuscular function in mouse models of CM, showing promise for treating related neuromuscular disorders in humans, justifying its further clinical development.
Muscle-specific kinase myasthenia gravis (MuSK MG) is caused by autoantibodies against MuSK in the neuromuscular junction (NMJ). MuSK MG patients have fluctuating, fatigable skeletal muscle weakness, in particular of bulbar muscles. Severity differs greatly between patients, in spite of comparable autoantibody levels.
View Article and Find Full Text PDF